Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and raises the price target from $13 to $16.
August 02, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Travere Therapeutics and raises the price target from $13 to $16.
The raised price target and maintained Outperform rating from a reputable analyst at Wedbush is likely to positively impact Travere Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100